Skip to content

EBITDA margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
27.2%-2.2pp
Labcorp Holdings logo
Labcorp HoldingsLH
15%+1.8pp
Quest Diagnostics logo
Quest DiagnosticsDGX
19.4%+0.6pp
NeoGenomics logo
NeoGenomicsNEO
-5.3%-85.9pp
Natera, Inc. logo
Natera, Inc.NTRA
-11.1%+0.5pp
GeneDx Holdings logo
GeneDx HoldingsWGS
-9%

Other financials

Income statement

See full
Revenue$71.1M-3.2%
Gross profit$21.5M-24.2%
Operating income-$34.6M-74.9%
Net income-$24.8M-115%
EPS (diluted)-$0.80-116%

Balance sheet

See full
Cash & equivalents$23.4M-65.2%
Total debt$8.2M+40.5%
Total equity$1.0B-6.9%
Total assets$1.2B-4.1%

Cash flow

See full
Operating cash flow$7.1M+260%
CapEx$5.2M+10.3%
Free cash flow$1.9M+121%

Valuation

See full
Market cap$552.11M-7.1%
Enterprise value$536.92M+0.7%
P/S1.7×-0.3×

Profitability

See full
Gross margin38.7%-0.1pp
Operating margin-33.1%+17.4pp
Net margin-23%+43.3pp
FCF margin-36.9%

Returns & leverage

See full
Return on equity-6.8%+48.2pp
Debt / equity0.0×
Current ratio5.3×-1.0×

Where this comes from

Calculated from Fulgent Genetics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Fulgent Genetics, Inc.'s ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Fulgent Genetics, Inc.'s EBITDA margin?
Fulgent Genetics, Inc. (FLGT) reported EBITDA margin of -25.5% in Q1 2026.
How has Fulgent Genetics, Inc.'s EBITDA margin changed year-over-year?
Fulgent Genetics, Inc.'s EBITDA margin decreased by 56.3% year-over-year, from -16.3% to -25.5%.
What is the long-term trend for Fulgent Genetics, Inc.'s EBITDA margin?
Over 5 years (2020 to 2025), Fulgent Genetics, Inc.'s EBITDA margin has grown at a -21.5% compound annual growth rate (CAGR), from 69.5% to -20.8%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.